Impacts of platinum-based chemotherapy on subsequent testicular function and fertility in boys with cancer

Title	Impacts of platinum-based chemotherapy on subsequent testicular function and fertility in boys with cancer
Authors	Lim Tian En, Mark F H Brougham, William Hamish B Wallace, Rod T Mitchell
Magazine	Human Reproduction Update
Date	09/16/2020
DOI	10.1093/humupd/dmaa041
Introduction	Children undergoing cancer treatment often face long-term infertility, particularly boys whose testicular function is impacted by chemotherapy. Currently, no established preventive measures exist. Platinum-based agents treat various childhood cancers but aren't included in the cyclophosphamide equivalent dose (CED), used to assess fertility risks posed by combination chemotherapy. This systematic literature review aimed to evaluate the effects of platinum-based cancer treatment on prepubertal testicular function and fertility. Searches in PubMed and EMBASE identified studies meeting criteria: boys aged ≤12 at treatment, exposed to platinum-based chemotherapy, and with reproductive function measurements. Of 1 449 articles, 20 studies met inclusion criteria, examining outcomes such as pregnancies, fatherhood, semen analysis, and hormonal function. Results suggest including platinum agents in clinical tools like CED for assessing gonadotoxicity. These findings guide fertility preservation strategies and treatment modifications to mitigate infertility risks in survivors.
Quote	Lim Tian En, Mark F H Brougham and William Hamish B W Wallace et al. Impacts of platinum-based chemotherapy on subsequent testicular function and fertility in boys with cancer. 2020. DOI: 10.1093/humupd/dmaa041
Element	Platinum (Pt)
Topics	Biomedical Materials
Industry	Pharmaceutical Industry